Teva Pharmaceutical Industries Ltd., of Jerusalem, said it enrolled the first patient in the Pride-HD study, a phase II trial designed to evaluate the impact of pridopidine, an oral, small molecule, on motor impairment in patients with Huntington's disease (HD).